Evidence map›Paper›PMID 26766909›Full record

ArticleInternational journal of nanomedicine2016

Improving cytotoxicity against cancer cells by chemo-photodynamic combined modalities using silver-graphene quantum dots nanocomposites.

Khaled Habiba, Joel Encarnacion-Rosado, Kenny Garcia-Pabon, Juan C Villalobos-Santos, Vladimir I Makarov, Javier A Avalos, Brad R Weiner, Gerardo Morell

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Frontiers in bioengineering and biotechnology · 2023
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Khaled HabibaDepartment of Physics, University of Puerto Rico - Rio Piedras Campus, San Juan, PR, USA; Molecular Sciences Research Center, University of Puerto Rico, San Juan, PR, USA.
Joel Encarnacion-RosadoMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR, USA; Department of Biology, University of Puerto Rico - Rio Piedras Campus, San Juan, PR, USA.
Kenny Garcia-PabonMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR, USA; Faculty of Education, University of Puerto Rico - Rio Piedras Campus, San Juan, PR, USA.
Juan C Villalobos-SantosMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR, USA; Department of Biology, University of Puerto Rico - Bayamon Campus, Bayamon, PR, USA.
Vladimir I MakarovDepartment of Physics, University of Puerto Rico - Rio Piedras Campus, San Juan, PR, USA.
Javier A AvalosMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR, USA; Department of Physics, University of Puerto Rico - Bayamon Campus, Bayamon, PR, USA.
Brad R WeinerMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR, USA; Institute for Functional Nanomaterials, University of Puerto Rico, San Juan, PR, USA; Department of Chemistry, University of Puerto Rico - Rio Piedras Campus, San Juan, PR, USA.
Gerardo MorellDepartment of Physics, University of Puerto Rico - Rio Piedras Campus, San Juan, PR, USA; Molecular Sciences Research Center, University of Puerto Rico, San Juan, PR, USA; Institute for Functional Nanomaterials, University of Puerto Rico, San Juan, PR, USA.
University of Puerto Rico at Río Piedras · PRUniversity of Puerto Rico System · PRUniversity of Puerto Rico at Bayamón · PR

Funding

UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Ilka C Rios · 2002 to 2026
$36.9M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Larkin Strong · 2002 to 2026
$23.8M
NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096297/CA096300NCI NIH HHS U54 CA096300
6 · The paper itself

Abstract

The combination of chemotherapy and photodynamic therapy has emerged as a promising strategy for cancer therapy due to its synergistic effects. In this work, PEGylated silver nanoparticles decorated with graphene quantum dots (Ag-GQDs) were tested as a platform to deliver a chemotherapy drug and a photosensitizer, simultaneously, in chemo-photodynamic therapy against HeLa and DU145 cancer cells in vitro. Ag-GQDs have displayed high efficiency in delivering doxorubicin as a model chemotherapy drug to both cancer cells. The Ag-GQDs exhibited a strong antitumor activity by inducing apoptosis in cancer cells without affecting the viability of normal cells. Moreover, the Ag-GQDs exhibited a cytotoxic effect due to the generation of the reactive singlet oxygen upon 425 nm irradiation, indicating their applicability in photodynamic therapy. In comparison with chemo or photodynamic treatment alone, the combined treatment of Ag-GQDs conjugated with doxorubicin under irradiation with a 425 nm lamp significantly increased the death in DU145 and HeLa. This study suggests Ag-GQDs as a multifunctional and efficient therapeutic system for chemo-photodynamic modalities in cancer therapy.

Indexed as

NanocompositesQuantum DotsAntineoplastic AgentsApoptosisCombined Modality TherapyDoxorubicinDrug Therapy, CombinationGraphiteHeLa CellsHumansPhotochemotherapyPhotosensitizing AgentsSilverSinglet OxygenAntineoplastic AgentsDoxorubicinGraphitePhotosensitizing AgentsSilverSinglet Oxygencancer therapydrug deliverymultifunctional nanoparticlesnanocompositesphotodynamic therapysilver nanoparticles

Identifiers

PMID26766909
PMCPMC4699517
OpenAlexW2212267647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.